This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


TMS Co., Ltd.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2017/5/19
Profile

Delegates :
Keiji Hasumi


Incorporated :
February  17 , 2005

Paid in Capital :
337 Million yen  

Employees :
5 人

Address :
211-10, Momura, Inagi-shi TOKYO
〒206-0804

TEL/FAX :
+81-42-306-5078 / +81-42-306-5078

URL:
http://www.tms-japan.co.jp/en/index.html

Attachment :

Mission/Background :
The mission of TMS is to enhance human wellness through new medical discoveries.
We are collaborating with Tokyo University of Agriculture and Technology, and develope a unique drug candidate from microbial library.
Ultimately, our goal is to help people suffering from a variety of diseases to recover their normal health and to improve their quality of life.

Technology & Business
We are developing small molecule drug candidates obtained from rich natural compound library at Tokyo University of Agriculture and Technology.
TMS-007 is an excellent stroke agent candidate with dual function, thrombolysis and cerebroprotection.
The P2 clinical trial of TMS-007 is ongoing.
Products & Service
Products & Service Name
Stage
Outline
Milestone
TMS-007
Phase2
TMS-007 is a novel stroke therapeutic drug candidate with dual mode of action, thrommbolysis and cerebroprotection.
Successful completion of phase 2 clinical trial.
TMS-00X
Discovery
TMS-00X is a novel small molecule with excellent anti-inflammation function.













Highlights
The phase I clinical trial of TMS-007 was completed successfully.
TMS-00X demonstrated excellent anti-inflammation efficacy with multiple animal models.
Hot news

Alliance strategy
We are seeking development partners both for TMS-007 and TMS-00X.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.